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Endovascular Treatment for Acute Ischemic Stroke
To the Editor: In the Mechanical Retrieval and 
Recanalization of Stroke Clots Using Embolec-
tomy (MR RESCUE) trial, reported by Kidwell et 
al. (March 7 issue),1 22 participating centers en-
rolled 118 patients during the period from 2004 
through 2011. Thus, on average, each participat-
ing center enrolled 1 patient every 16 months. 
This extremely low rate may suggest that inclu-
sion in the trial was selective and not representa-
tive of patients with stroke in general. This no-
tion is supported by the poor outcomes reported 
for both forms of treatment in the study. A good 
clinical outcome, defined as a 90-day score of 2 or 
less on the modified Rankin scale (ranging from 
0 [no symptoms] to 6 [death]), was achieved in 44% 
of the patients in the Local versus Systemic Throm-
bolysis for Acute Ischemic Stroke (SYNTHESIS 
Expansion) trial reported by Ciccone et al.2 and 
in 42% of the patients in the Interventional Man-
agement of Stroke (IMS) III trial reported by 
Broderick et al.3 in the same issue. However, the 
corresponding proportion in the MR RESCUE 
study was only 19%. Assessment of a diagnostic 
tool with ineffective treatment methods will make 
even a very valuable diagnostic tool appear to be 
useless.4 Accordingly, when the value of perfusion 
imaging is addressed in a population in which 
neither of the treatment methods under study ap-
pears to work, the validity of the entire study may 
be questionable. Unfortunately, neither the authors 
of the MR RESCUE study nor Chimowitz,5 in the 
corresponding editorial, addresses this threat to 
the generalizability of the results.
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To the Editor: In these three randomized trials 
of endovascular treatments for acute ischemic 
stroke, limited information was provided about 
anesthetic management. For example, results were 
not adjusted for the use of sedation, anesthesia, 
or both.
We recently performed a survey in France that 
showed that the use of sedation or general anes-
thesia appears to be a prevailing practice during 
endovascular procedures for stroke (unpublished 
data). Recent studies have reported worse out-
comes in patients who received general anesthesia 
for endovascular procedures. The basis for this 
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association remains unclear, especially because 
of the nonrandomized nature of the published 
studies.1-4 A nonexhaustive list of hypotheses 
includes delays in treatment, risks related to intu-
bation, hemodynamic changes, or specific effects 
of anesthetic drugs that could interfere with in 
situ fibrinolytic agents.5 Until prospective, ran-
domized studies that address the effect of anes-
thetic agents in acute ischemic stroke are under-
taken, we suggest that trials that evaluate 
endovascular strategies should standardize and 
report the regimens of these agents to allow 
secondary analyses.
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Caen, France 
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To the Editor: Two of the reasons for the failure 
to prove the efficacy of endovascular treatment 
in these three randomized trials are the use of 
first-generation devices and the delayed (in the 
studies by Broderick et al. and Ciccone et al.) or 
absent (in the study by Kidwell et al.) introduc-
tion of new techniques in the study protocols. 
Recent randomized studies have clearly shown 
that stent retrievers were more efficacious than 
the Merci device.1,2 Stent retrievers were used in 
4 patients in the IMS III trial and in 23 patients 
in the SYNTHESIS Expansion trial; they were not 
allowed in MR RESCUE.
Furthermore, the large proportion of patients 
in whom there was a very long time from the 
start of intravenous thrombolysis to groin punc-
ture indicates that the best clinical pathways 
were not used in several study sites. In addition, 
cross-sectional angiography before random as-
signment of patients to intravenous or interven-
tional treatment should be mandatory.
In summary, we think that in all three trials, 
intravenous thrombolysis was not compared with 
best endovascular treatment. Further randomized, 
controlled trials should be based on modern 
concepts of imaging in patients with stroke and 
should continuously incorporate new devices.
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To the Editor: Kidwell et al. completed a rigor-
ous, randomized evaluation of imaging-based 
treatment selection. However, their conclusion 
that penumbral-imaging selection did not iden-
tify a subpopulation of patients who would have 
a favorable response to endovascular therapy for 
stroke conflicts with previous findings.1-3 The 
MR RESCUE trial did show significantly better 
outcomes in patients with a favorable penumbral 
pattern when recanalization occurred; these find-
ings were consistent with those of previous stud-
ies, despite relatively large infarcts at baseline 
and a complex “penumbral selection” method. 
Interpretation of these data and the apparent re-
sponse to recanalization in the nonpenumbral 
group is hampered by a lack of reported baseline 
characteristics for these subgroups. In addition, 
the key cofactors of reperfusion and recanaliza-
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tion were assessed late (at 7 days) when sponta-
neous recanalization was common and perhaps 
nonnutritional. Early recanalization holds the key 
to improved outcomes, and the low rate (27%) of 
good-quality postprocedural revascularization in 
MR RESCUE (a score of 2b to 3 on the Throm-
bolysis in Cerebral Infarction [TICI] scale, which 
ranges from 0 [no perfusion] to 3 [full perfusion]) 
is in stark contrast to results achieved with newer 
devices.4 Ongoing studies such as Extending the 
Time for Thrombolysis in Emergency Neuro-
logical Deficits — Intra-Arterial (EXTEND-IA) 
(ClinicalTrials.gov number, NCT01492725) and 
Solitaire FR as Primary Treatment for Acute Ische-
mic Stroke (SWIFT PRIME) (NCT01657461) are 
using penumbral-imaging selection with more 
effective devices, and we await the results with 
interest.
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To the Editor: Broderick et al. and Ciccone et al. 
described studies comparing intravenous tissue 
plasminogen activator (t-PA) alone with intrave-
nous t-PA plus endovascular treatment for acute 
ischemic stroke, and they found no advantage 
with endovascular treatment. These studies in-
clude patients with both large and small distal-
vessel occlusions who probably benefit from 
 different treatment approaches. Stent-based throm-
bectomy, the state-of-the-art endovascular ap-
proach, was used in only a handful of patients. 
Because of these limitations, both studies should 
be viewed with caution.
Intravenous t-PA improves outcomes in patients 
with mild-to-moderate stroke by recanalizing 
small-to-midsize arteries; however, its efficacy 
in recanalizing major large-vessel strokes is limit-
ed. Outcomes with early endovascular techniques 
— intraarterial thrombolysis and mechanical 
thrombectomy — were limited by long procedure 
times.
The newest stent-based thrombectomy devices 
allow unprecedented rapid complete recanaliza-
tion rates (Thrombolysis in Myocardial Infarction 
risk score, 3 on a scale of 0 to 3, with 0 indicat-
ing no flow and 3 normal flow; TICI score, 2b 
to 3) in occlusions of the proximal middle cere-
bral artery. We found that stent-based thrombec-
tomy provides superior outcomes as compared 
with intravenous t-PA in these patients,1 with 
good functional outcome (a score of 0 to 2 on 
the modified Rankin scale, which ranges from 
0 to 6, with higher scores indicating greater dis-
ability) in the majority of patients.2 The SWIFT 
study also showed superior results with current 
devices as compared with the Merci device.3 
Rapid recanalization with stent-based thrombec-
tomy appears to improve outcomes.
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Dr. Broderick and Colleagues Reply: The 
IMS III trial was designed to test the approach of 
endovascular therapy after intravenous t-PA as 
compared with intravenous t-PA alone because 
we anticipated the rapid evolution of Food and 
Drug Administration (FDA)–cleared endovascular 
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technology for clot removal during the course of 
the trial, which did occur. Unfortunately, our 
trial was halted prematurely for futility after only 
a handful of patients had been treated with the 
trial-approved Solitaire stent-retriever device, and 
we agree that the trial cannot address the effi-
cacy and safety of the devices. However, many 
interventionalists did not participate in our study 
because they believed that the older endovascular 
approaches were superior to intravenous t-PA 
alone, which the trial did not show. Randomized 
trials of the new endovascular technology as 
compared with intravenous t-PA alone, including 
SWIFT PRIME and Assess the Penumbra System 
in the Treatment of Acute Stroke (THERAPY; 
NCT01429350), are ongoing.
We agree with the importance of vascular 
imaging before treatment in clinical trials of 
endovascular therapy. When our study began in 
2006, few centers used computed tomographic 
(CT) angiography as part of the standard evalu-
ation of patients with acute stroke.1 For this 
reason, we used a score of 10 or more on the 
National Institutes of Health Stroke Scale (ranging 
from 0 [no neurologic deficit] to 42 [maximum 
possible deficit]) to identify patients with a high 
likelihood of an intracranial artery occlusion on 
angiography after intravenous t-PA. The use of CT 
angiography as a diagnostic tool dramatically 
increased during the trial, and we incorporated 
its use so that nearly half the trial patients under-
went vascular imaging before treatment. In a 
prespecified analysis, we found no significant 
difference in outcomes in patients with a pretreat-
ment occlusion of the internal carotid artery, 
proximal middle cerebral artery, or basilar artery.
Our study, which included many of the most 
experienced sites in the world with regard to 
endovascular therapy, emphasized rapid therapy 
in its design, but it still had a longer time to the 
start of endovascular therapy than the smaller, 
single-group IMS I2 and II3 trials. We agree that 
minimization of the time to the start of endo-
vascular therapy will be critical to show its ef-
ficacy, and we recommend critical examination 
of the delivery of stroke care in the United 
States, in which patients are commonly treated 
with intravenous t-PA at a community hospital 
and then are transported to a tertiary center for 
additional endovascular therapy.
We agree with Gakuba and colleagues about 
the role of general anesthesia in endovascular 
therapy.
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Drs. Ciccone and Valvassori Reply: We were 
glad to contribute to the evidence on the effi-
cacy of endovascular treatment for stroke. The 
SYNTHESIS Expansion investigators have worked 
with great enthusiasm, even though the results 
were different from what was expected. We ex-
pected to confirm the common perception of the 
superiority of endovascular treatment over intra-
venous t-PA. Our findings confirm the impor-
tance of conducting randomized, controlled trials 
in this area. The comparative trials of old- and 
new-generation retrievers for thrombectomy re-
vascularization (Trevo vs. Merci and Solitaire vs. 
Merci) described by Arnold et al. favor this erro-
neous perception. If endovascular therapy is in-
tended to be stent-based thrombectomy with de-
vices such as Trevo and Solitaire, then the first 
step in showing the efficacy of endovascular 
therapy, in our view, would be to show, with a 
well-designed, randomized, controlled trial, that 
stent retrievers are superior to intravenous t-PA in 
patients with large-vessel stroke. Unfortunately, 
the studies cited by Cohen and Leker which fa-
vored thrombectomy were not randomized, con-
trolled trials and as such have many types of bias, 
as described by Mullen et al. in their systematic 
review.1
The investigators in our trial aimed to pro-
duce evidence that would support the diffusion 
of endovascular treatment to reduce the stroke 
burden nationwide, not in a subgroup of patients 
with ischemic stroke. We were not interested in a 
specific device; our study pragmatically allowed 
the use of the devices that were available on the 
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market at the time of the study and, inevitably, its 
results are related to the devices available when 
it was conducted.
The invitation by Gakuba et al. to perform a 
subgroup analysis involving patients who received 
anesthesia should be considered with caution: 
different institutions have different treatment 
protocols that are not always related to the clini-
cal status of the patients. In some centers, pa-
tients in critical condition are more likely to 
undergo intubation; thus, bias is introduced in 
the analyses.
The same difficulties could be encountered in 
evaluating the subgroup of patients in whom 
stent retrievers were used in our trial: they were 
used mostly in the last part of the trial and only 
in a few centers. Even if the results seem slightly 
more encouraging in this subgroup, the numbers 
are definitely too small to draw conclusions.
Overall, we are in agreement with the accom-
panying editorial by Chimowitz, and we think 
that these three trials are not the end of trials of 
endovascular therapy but are rather a stimulus 
for new randomized, controlled trials of the use 
of the endovascular approach.
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Dr. Kidwell and Colleagues Reply: With re-
gard to recruitment and possible selection bias: 
the average recruitment rate per site was 1 pa-
tient every 8 months, since not all sites were ac-
tive throughout the trial. There is as much, if not 
more, reason to be concerned about selection bias 
toward milder cases of stroke in other studies, 
including the Diffusion and Perfusion Imaging 
Evaluation for Understanding Stroke Evaluation 
(DEFUSE 2) trial1 and the study of tenecteplase 
reported by Parsons et al.2 In the latter study, 
2768 patients were screened and 75 were en-
rolled. The rate of good outcomes in the MR 
RESCUE trial cannot be directly compared with 
those of the IMS III and SYNTHESIS Expansion 
trials, which had shorter enrollment time win-
dows and differing inclusion and exclusion criteria. 
We agree that the issue of generalizability for all 
imaging-based studies requires further scrutiny.
We agree with the concern raised regarding 
the potential effect of anesthesia management 
on outcome. We did collect information on an-
esthesia management in MR RESCUE, since there 
was reluctance from the endovascular commu-
nity (endovascular surgeons, anesthesiologists, 
and interventional radiologists and neurologists) 
to adopt a single standard approach when our 
trial was conducted.
Our trial continuously updated the protocol to 
include newly available devices coincident with 
FDA clearances throughout the trial; stent re-
trievers entered practice only as enrollment was 
being completed. We concur that the results re-
flect the performance of first-generation neuro-
thrombectomy technology.
With regard to the letter by Campbell et al.: 
we do not agree that our trial results conflict 
with previous findings. The Echoplanar Imaging 
Thrombolytic Evaluation Trial (EPITHET) was a 
negative study that did not include a sufficient 
number of patients with a nonpenumbral pattern 
to test the imaging-selection hypothesis; there-
fore, no strong conclusions can be drawn from 
this study regarding penumbral-imaging selec-
tion.3 Similarly, the DEFUSE4 and DEFUSE 21 
trials lacked control groups; no conclusions can 
be made definitively regarding the interaction of 
imaging selection and treatment for acute stroke 
versus control. We agree that early recanalization 
is likely to have the most benefit in patients with 
acute stroke.
In conclusion, as stated previously, we strong-
ly endorse further randomized, controlled trials 
with new-generation devices to test both the ef-
ficacy of endovascular approaches to treatment 
for stroke and the full spectrum of the imaging-
selection hypothesis. We have substantial con-
cerns about studies that select for enrollment a 
priori only patients with penumbra-imaging pat-
terns. Without definitive proof of the hypothesis 
of penumbral-imaging selection, these studies 
could lead to misleading conclusions not only 
about imaging selection, but also about the 
criteria regarding which patients may benefit.
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Antibiotics for Uncomplicated Severe Malnutrition
To the Editor: Trehan et al. (Jan. 31 issue)1 
found that amoxicillin or cefdinir improved 
 recovery from severe malnutrition among chil-
dren in Malawi. The hypothesized reasons for 
their effectiveness include an underlying im-
munodeficiency related to malnutrition.1,2 How-
ever, although a major cause of immunodefi-
ciency in Malawi is the human immunodeficiency 
virus (HIV), 68% of enrolled children were not 
tested for HIV; among those tested, 22% had 
HIV infection. Children known to be infected 
with HIV had the highest risk of treatment fail-
ure or death. Malnutrition is a well-known con-
dition in children with HIV disease; outpatient 
therapeutic programs are important venues for 
the identification of infected children.3 Un-
fortunately, incomplete ascertainment of HIV 
status and inadequate management of infection 
in children, including trimethoprim–sulfameth-
oxazole prophylaxis, antiretroviral therapy (ART), 
or both, may confound the interpretation of the 
trial findings. The proper management of HIV 
infection could modify the effect of amoxicillin 
and cefdinir, and ART can improve weight gain 
and be lifesaving in infected children.2 Offering 
HIV testing (and referral for HIV care for those 
infected) is an internationally accepted practice 
in clinical trials and is consistent with Malawi’s 
national HIV testing and treatment guide-
lines.3,4 It would, therefore, be helpful to know 
why testing was not performed.
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Centers for Disease Control and Prevention 
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To the Editor: Trehan et al. concluded that anti-
biotics should be used routinely with ready-to-use 
therapeutic food (RUTF) for severe malnutrition 
in outpatients, irrespective of concomitant infec-
tious disease. Augmentation of RUTF is sorely 
needed,1 but we question the magnitude of the 
benefit and suggest that it be weighed against 
alternative interventions and the likely costs of 
increased antibiotic resistance.
The researchers reported that adding a 7-day 
antibiotic course to RUTFs resulted in significant 
reductions in mortality and increases in recovery 
rates. Careful analysis of the findings, however, 
shows that among survivors, the differential in 
the rate of treatment failure between the anti-
biotic treatment groups and the placebo group 
was less than 1%. In addition, the study fails to 
take into account infections, breast-feeding, and 
status with regard to HIV and AIDS.
Given the high prevalence of moderate and re-
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